- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 43
- States / cities
- Mobile, Alabama • Tucson, Arizona • La Jolla, California + 32 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2497–2520
of 7,251
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Respiratory Viral Infection
- Interventions
- No Intervention
- Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Detroit, Michigan • Seattle, Washington
- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel, tirapazamine
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 93
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
- Interventions
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment
- Drug · Biological · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 640
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 456 more
- Conditions
- Healthy
- Interventions
- Light Source B: Visible Light solar simulator (VL + UVA1), Light Source A: Visible Light solar simulator closer match to sunlight (VL +UVA1)
- Device
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- gefitinib
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 43 more
- Conditions
- Head and Neck Cancer
- Interventions
- cisplatin, paclitaxel, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 21 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 215
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
- Conditions
- Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
- Interventions
- Emricasan, Placebo
- Drug
- Lead sponsor
- Histogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 22
- States / cities
- Pasadena, California • Rialto, California • Palmetto Bay, Florida + 16 more
- Conditions
- Neoplasms
- Interventions
- Dostarlimab
- Biological
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 729 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 38 more
- Conditions
- Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
- Interventions
- Assessment of Therapy Complications, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 25,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 163
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 124 more
- Conditions
- Healthy
- Interventions
- Not listed
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Kidney Cancers
- Interventions
- 5-Aminolevulinic acid Hydrochloride (Gliolan®)
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Cystic Fibrosis
- Interventions
- VX-121/TEZ/D-IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Cystic Fibrosis
- Interventions
- Observational
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 31 more
- Conditions
- Facial Papulopustular Rosacea
- Interventions
- FMX103 minocycline foam 1.5%, Vehicle foam
- Drug
- Lead sponsor
- Vyne Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 771 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 46
- States / cities
- Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 39 more
- Conditions
- Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
- Interventions
- BT5528, Nivolumab
- Drug
- Lead sponsor
- BicycleTx Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 12
- States / cities
- Encinitas, California • Orange, California • Denver, Colorado + 9 more
- Conditions
- Persistent Asthma
- Interventions
- German cockroach allergenic extract, Placebo for German cockroach allergenic extract
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Colorectal Adenocarcinoma
- Interventions
- VVD-133214, Pembrolizumab
- Drug
- Lead sponsor
- Vividion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Ann Arbor, Michigan • Detroit, Michigan + 1 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Reldesemtiv, Placebo
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 489 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 30 more
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Nicole Hamblett
- Other
- Eligibility
- 4 Months and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 43 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- INCAGN01876, retifanlimab
- Biological
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • La Jolla, California • Palo Alto, California + 14 more
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- MBG453, Azacitidine, Decitabine, INQOVI (oral decitabine)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 10 more
- Conditions
- Lymphoma
- Interventions
- aldesleukin, filgrastim, recombinant interferon gamma, carmustine, cyclosporine, cytarabine, etoposide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more